AstraZeneca shared a post on LinkedIn:
“Transforming care in haematology requires pushing the boundaries of science and applying deep disease understanding.
At ASH25, new data will spotlight next-generation modalities, including T-cell engagers and cell therapies and explore their potential to redefine care and reduce the treatment burden across a spectrum of diseases, including blood cancer, immune-mediated conditions and rare diseases.
Learn more about our commitment to improving outcomes for people living with haematological disease.”
More posts about ASH25.